Crisaborole Ointment for Skin Toxicity Induced by Cetuximab
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Metastatic Colorectal Cancer
Related studies linked through entity extraction aliases.
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Fruquintinib in the Cross-line Treatment of Refractory mCRC
- Status
- RECRUITING
- Phase
- N/A
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
- Status
- RECRUITING
- Phase
- PHASE1
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
- Status
- RECRUITING
- Phase
- PHASE2
Nitazoxanide in Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States
- Status
- COMPLETED
- Phase
- N/A
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
- Status
- RECRUITING
- Phase
- PHASE1
Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC
- Status
- RECRUITING
- Phase
- PHASE2
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
- Status
- RECRUITING
- Phase
- PHASE2
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of OB-002 in Patients With Refractory Metastatic Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1
The Impact of Radiotherapy on Oligometastatic Cancer
- Status
- RECRUITING
- Phase
- N/A
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- N/A
Circulating Tumor Cells and Neutrophils Count for Colorectal Metastatic Cancer
- Status
- COMPLETED
- Phase
- N/A
ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases
- Status
- RECRUITING
- Phase
- N/A
Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2